Reisner Y, Martelli M F
Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Curr Opin Immunol. 2000 Oct;12(5):536-41. doi: 10.1016/s0952-7915(00)00135-7.
Early studies in murine models and more recent clinical data in heavily pre-treated leukemia patients have shown that escalation of the dose of hematopoietic progenitor cells can overcome major genetic barriers and enable rapid and durable engraftment of haploidentical, three-locus-mismatched transplants without graft-versus-host disease. In vitro studies suggest that veto cells within the progenitor population most probably mediate this facilitating effect.
早期在小鼠模型中的研究以及近期针对经过大量预处理的白血病患者的临床数据表明，增加造血祖细胞的剂量能够克服主要的基因障碍，并使单倍体相合、三位点不匹配的移植快速且持久地植入，同时不会引发移植物抗宿主病。体外研究表明，祖细胞群体中的否决细胞很可能介导了这种促进作用。
